TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31724347
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (flunarizine hydrochloride capsule, 5 mg once a day)
Study: 23813194
Drug: PROMPT treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROMPT treatment with TKP cues
Study: 23813194
Drug: PROMPT treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROMPT treatment without TKP cues
Study: 21477425
Drug: Suspension-type comparators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension-type comparators (budesonide [Rhinocort Aqua] or azelastine + budesonide [Astelin] + Rhinocort Aqua)
Study: 18648229
Drug: Droperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1 mg)
Study: 18648229
Drug: Droperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1 mg) + Ondansetron (4 mg)
Study: 17050796
Drug: Digoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.5 mg oral) administered individually
Study: 17050796
Drug: Midazolam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2.0 mg oral) administered individually
Study: 10588635
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg twice a day)
Study: 10588635
Drug: Seratrodast (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seratrodast (80 mg once a day)
Study: 7847430
Drug: Plasma glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma glucose level at 2.2 mmol/L
Study: 7847430
Drug: Plasma glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma glucose level at 8.9 mmol/L
Study: 7847430
Drug: Plasma glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma glucose levels (14.4 and 21.1 mmol/L)
Study: 2114625
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of steroids
Study: 2114625
Drug: Urokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase and no accompanying treatment
Study: 30696682
Drug: Bortezomib add-on
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib add-on to pre-existing therapy
Study: 22341199
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use reduction
Study: 19398689
Drug: Computerized medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized medication reconciliation tool and process redesign
Study: 19398689
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medication reconciliation process)
Study: 19398689
Drug: Computerized medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized medication reconciliation tool and process redesign at hospital 1
Study: 19398689
Drug: Computerized medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized medication reconciliation tool and process redesign at hospital 2
Study: 15976206
Drug: Ondansetron oral
Normalized name: Ondansetron Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron oral disintegrating tablets (4 mg)
Study: 12688134
Drug: 3 micrograms/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms/kg/day of hGH (biosynthetic human growth hormone‐‐Humatrope)
Study: 12688134
Drug: 6 micrograms/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 micrograms/kg/day of hGH (biosynthetic human growth hormone‐‐Humatrope)
Study: 7616301
Drug: Beta-carotene (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (120 mg)
Study: 7616301
Drug: UV light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV light exposure (three times the minimal erythema dose)
Study: 24490380
Drug: LVD 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVD 100 mg daily
Study: 24490380
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine colligative treatment only)
Study: 25323181
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's (LR) solution
Study: 17130190
Drug: Losartan/Hydrochlorothiazide (L/H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/Hydrochlorothiazide (L/H)
Study: 12650165
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetylsalicylic acid (ASA) and clopidogrel
Study: 12650165
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA and ticlopidin
Study: 10390287
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose vitamin A supplementation (10,000 IU)
Study: 28709466
Drug: 7% inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% inhaled hypertonic saline (HS - 4 ml 7% sodium chloride)
Study: 26181507
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (2000 pulses per session, 1-Hz daily for 10 consecutive workdays)
Study: 26181507
Drug: Placebo rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rTMS (2000 pulses per session, 1-Hz daily for 10 consecutive workdays)
Study: 21392075
Drug: Sirukumab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab (0.3, 1, 3, 6 or 10 mg kg(‐1) intravenous infusion)
Study: 11136497
Drug: Ticlopidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 200 mg/d
Study: 9576148
Drug: High-serum-ECP group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-serum-ECP group (serum level of ECP > 15.7 ng/mL)
Study: 7935656
Drug: Troglitazone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone, 200 mg orally twice daily for 12 weeks
Study: 25800762
Drug: Early palliative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early palliative care intervention (three structured weekly telephone coaching sessions, monthly follow‐up, and a bereavement call)
Study: 25800762
Drug: Delayed palliative
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed palliative care intervention (three structured weekly telephone coaching sessions, monthly follow‐up, and a bereavement call starting 3 months after enrollment)
Study: 12115394
Drug: L-758,298 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-758,298 100 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + MK-869 300 mg orally on Days 2-5
Study: 12115394
Drug: L-758,298 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-758,298 100 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + placebo on Days 2-5
Study: 12115394
Drug: ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 32 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + placebo on Days 2-5
Study: 10470656
Drug: 5'‐DFUR (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR (1200 mg/day) administered for more than 5 days before operation
Study: 8682234
Drug: 10 mcg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mcg/Kg of atropine in 60 seconds (Group 1)
Study: 8682234
Drug: 15 mcg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg/Kg of atropine in 120 seconds (Group 2)
Study: 8682234
Drug: 20 mcg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg/Kg of atropine in 120 seconds (Group 3)
Study: 8682234
Drug: 20 mcg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg/Kg of atropine in 120 seconds (Group 4, with full-dose oral beta-blocker therapy)
Study: 31901783
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy using a surgical glove (SG) for 90 minutes
Study: 31152672
Drug: Green lentil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green lentil chili (61.8 g)
Study: 31152672
Drug: Red lentil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red lentil chili (54 g)
Study: 31152672
Drug: Muffin treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muffin treatments (wheat replaced with lentils)
Study: 28158893
Drug: Curcumin (phytosomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (phytosomal form; 1000 mg/day in 2 divided doses)
Study: 19228872
Drug: CoQ(10) supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) supplementation (200 mg/day)
Study: 15260084
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of oral tizanidine as premedication 60 minutes before arrival in the operating room
Study: 9175566
Drug: Minoxidil combined
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil combined with a diuretic (n = 10)
Study: 1494770
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 5 mg
Study: 2858710
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dipyridamole and 150 mg aspirin daily from 3 months' gestation onwards (group A)
Study: 2858710
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B, no treatment)
Study: 29090661
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy plus patent foramen ovale closure (with GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder)
Study: 23747481
Drug: Vaniprevir 125
Normalized name: Vaniprévir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir 125 mg qd
Study: 23747481
Drug: Vaniprevir 600
Normalized name: Vaniprévir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir 600 mg qd
Study: 23747481
Drug: Vaniprevir 25
Normalized name: Vaniprévir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir 25 mg bid
Study: 23747481
Drug: Vaniprevir 75
Normalized name: Vaniprévir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir 75 mg bid
Study: 23747481
Drug: Vaniprevir 250
Normalized name: Vaniprévir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir 250 mg bid
Study: 23747481
Drug: Vaniprevir 500
Normalized name: Vaniprévir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir 500 mg bid
Study: 23747481
Drug: Vaniprevir 700
Normalized name: Vaniprévir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vaniprevir 700 mg bid
Study: 11398777
Drug: Topical papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical papaverine application
Study: 2514152
Drug: Hypoxic gas
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic gas inhalation (HC: FIO2 is 16.0% in N2)
Study: 28712103
Drug: Ultrasound-guided interscalene
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided interscalene brachial plexus block (IBPB) with 20 mL of 0.5% ropivacaine (group U)
Study: 28712103
Drug: Peripheral nerve
Normalized name: Peripheral nerve antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral nerve stimulation (PNS)‐confirmed IBPB with 20 mL of 0.5% ropivacaine (group N)
Study: 28712103
Drug: Ultrasound-guided, PNS‐confirmed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided, PNS‐confirmed IBPB (dual guidance) with 20 mL of 0.5% ropivacaine (group NU)
Study: 24722769
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical nutrition therapy (IMNT)
Study: 23695772
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg daily for 2 weeks, then increased to maximum daily dose for 4 weeks)
Study: 23695772
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg daily for 2 weeks, then increased to maximum daily dose for 4 weeks)
Study: 22080023
Drug: Zinc levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc levels at 137, 309, and 655 mg/kg
Study: 16490951
Drug: Citicoline 1
Normalized name: citicoline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 1 g/12 h for 2 weeks (orally or intravenously)
Study: 27838224
Drug: Vismodegib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (150 mg/day)
Study: 27838224
Drug: Vismodegib (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (continuous dosing)
Study: 27838224
Drug: Vismodegib (interrupted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (interrupted dosing)
Study: 22098444
Drug: TGD 300
Normalized name: tgDCC-E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGD 300 mg/day
Study: 22098444
Drug: TGD 900
Normalized name: tgDCC-E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGD 900 mg/day
Study: 20845295
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sublingual isosorbide dinitrate (ISDN)
Study: 10366992
Drug: Tiagabine HCl
Normalized name: tiagabine HCl
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine HCl 10 mg
Study: 10366992
Drug: Tiagabine HCl
Normalized name: tiagabine HCl
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine HCl 10 mg with triazolam 0.125 mg
Study: 2471894
Drug: Oxprenolol (monotherapy)
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol (monotherapy)
Study: 2192098
Drug: Chlorthalidone (monotherapy)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (monotherapy)
Study: 2471894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxprenolol and chlorthalidone
Study: 1201766
Drug: Insulin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 160 ng/min. (INS)
Study: 1201766
Drug: Insulin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 160 ng/min. (INS) + Secretin 12 ng/min. (SEC)
Study: 19276664
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine (n = 182)
Study: 7858335
Drug: Hemodiafiltration (Qb:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodiafiltration (Qb: 400 ml/min, Qd: 800 ml/min, time: 3.5 hours, 10 L hemofiltrate exchanges with Ringer's lactate or combination of Ringer's solution and saline using polysulfone membrane dialyzer)
Study: 28609608
Drug: Inhaled voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled voriconazole (40 mg b.i.d. for 2 days)
Study: 28609608
Drug: Oral voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral voriconazole (400 mg on day 1, 200 mg on day 2, b.i.d.)
Study: 21315002
Drug: Hengyan medicinal
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hengyan medicinal recipe 50 ml, 3 times daily for 7 days
Study: 21315002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with western medicine
Study: 19692911
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) during physical therapy sessions
Study: 19692911
Drug: No Virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Virtual Reality (no VR) during physical therapy sessions
Study: 15355469
Drug: Cat allergen
Normalized name: Anti-cat allergen fel d 1 monoclonal anitbody regn-1908
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cat allergen peptide immunotherapy
Study: 15355469
Drug: CD4(+) CD25(+)
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4(+) CD25(+) T cells (both before and after therapy)
Study: 11695713
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation of acyclovir (200mg)
Study: 11695713
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of acyclovir (100mg)
Study: 2022560
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment (0.07 U/kg body wt daily)
Study: 30108337
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity Extracorporeal Shockwave Therapy (Li‐ESWT)
Study: 30108337
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity Extracorporeal Shockwave Therapy (Li‐ESWT) and Sham therapy
Study: 28935843
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab (1,400 mg cycles 2-8)
Study: 28935843
Drug: Intravenous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous rituximab (375 mg/m2 cycles 1-8)
Study: 25056361
Drug: Dukoral vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dukoral vaccine
Study: 22491729
Drug: 8-week stress
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week stress management program (relaxation breathing and progressive muscle relaxation, twice a day)
Study: 11936019
Drug: TETRActHIB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETRActHIB vaccine
Study: 10357402
Drug: Etoposide, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, 120 mg/m2 i.v. on Days 1-3; 5-fluorouracil, 500 mg/m2 i.v. on Days 1-3; folinic acid, 300 mg/m2 i.v. on Days 1-3; GM-CSF 250 microg/m2/day for 14 days if Grade 4 neutropenia occurred.
Study: 8825274
Drug: Flunarizine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (50 mg daily intravenous for 1 week, followed by 21 mg daily oral for week 2, and 7 mg daily oral for weeks 3-4)
Study: 8825274
Drug: Flunarizine (subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (subgroup receiving treatment within 6 hours)
Study: 8825274
Drug: Placebo (subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subgroup receiving treatment within 6 hours)
Study: 1582280
Drug: 800 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms of triamcinolone acetonide daily
Study: 1582280
Drug: 1200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 micrograms of triamcinolone acetonide daily
Study: 1582280
Drug: 1600 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 micrograms of triamcinolone acetonide daily
Study: 26847689
Drug: LSD (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (75 µg, intravenously)
Study: 16716604
Drug: Glucagon (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.5 mg IV bolus)
Study: 16716604
Drug: Glucagon (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.5 mg IV bolus) repeated 7 hours later
Study: 10213463
Drug: IFN-alpha2 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2 treatment for 8 weeks
Study: 6770409
Drug: Neogynon (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neogynon (a type of Oral Contraceptive)
Study: 31517847
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (WC)
Study: 19505589
Drug: Antiretroviral DOT
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral DOT (directly observed therapy)
Study: 7837397
Drug: Ulinastatin (300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (300,000 units added in the priming solution)
Study: 2452940
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs started within 8 days after 131I
Study: 25546524
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with low-dose bupivacaine and fentanyl
Study: 23024014
Drug: Weekly alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly alcohol intake (10 units/week increase)
Study: 18477075
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid resuscitation guided by hourly urine output (HUO Group, n=12)
Study: 15909462
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring with low dose progesterone (1.8 g)
Study: 15909462
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring with high dose progesterone (3.6 g)
Study: 15909462
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring (both doses)
Study: 10594396
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg o.d.)
Study: 10594396
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg o.d.) and Ranitidine (300 mg b.d.)
Study: 1719288
Drug: Oral bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisoprolol (20 mg) at rest
Study: 1719288
Drug: Oral bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisoprolol (20 mg) with iterative stress tests
Study: 84441
Drug: DTIC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC alone or in combination with other cytotoxic agents (Oncovin, Bleomycin, Adriblastin)